A Phase 1 Study of DB-2304 in Healthy Adults and SLE Participants
Status:
RECRUITING
Trial end date:
2026-06-05
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single Ascending Dose and Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DB-2304 Injection in Healthy Adults and Systemic Lupus Erythematosus Adult Participants